Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1960 2
1961 1
1962 3
1963 10
1964 12
1965 10
1966 7
1967 6
1968 20
1969 27
1970 16
1971 28
1972 29
1973 12
1974 13
1975 15
1976 19
1977 28
1978 34
1979 30
1980 24
1981 17
1982 12
1983 26
1984 25
1985 17
1986 18
1987 29
1988 27
1989 29
1990 28
1991 50
1992 42
1993 48
1994 47
1995 76
1996 100
1997 97
1998 143
1999 191
2000 203
2001 227
2002 333
2003 375
2004 411
2005 486
2006 589
2007 652
2008 725
2009 805
2010 981
2011 1115
2012 1309
2013 1452
2014 1762
2015 1885
2016 1982
2017 2101
2018 2220
2019 2327
2020 2733
2021 2663
2022 8
Text availability
Article attribute
Article type
Publication date

Search Results

25,789 results
Results by year
Filters applied: . Clear all
Page 1
Metformin in 2019.
Flory J, Lipska K. Flory J, et al. JAMA. 2019 May 21;321(19):1926-1927. doi: 10.1001/jama.2019.3805. JAMA. 2019. PMID: 31009043 Free PMC article. Review.
Metformin was also taken off the US market due to concerns over lactic acidosis, but it subsequently has been proven safe and effective in lowering glucose levels and was reintroduced in 1995. Optimal metformin use requires clear understanding of its effects, dosing
Metformin was also taken off the US market due to concerns over lactic acidosis, but it subsequently has been proven safe and effecti
Metformin - its potential anti-cancer and anti-aging effects.
Podhorecka M, Ibanez B, Dmoszyńska A. Podhorecka M, et al. Postepy Hig Med Dosw (Online). 2017 Mar 2;71(0):170-175. doi: 10.5604/01.3001.0010.3801. Postepy Hig Med Dosw (Online). 2017. PMID: 28258677 Free article. Review.
The generally accepted mechanism of metformin's effect is stimulation of adenosine monophosphate (AMP)-activated protein kinase (AMPK). ...Lately, many novel pathways, besides AMPK induction, have been revealed, which can explain some of metformin's be …
The generally accepted mechanism of metformin's effect is stimulation of adenosine monophosphate (AMP)-activated protein kinas …
Metformin and Its Benefits for Various Diseases.
Lv Z, Guo Y. Lv Z, et al. Front Endocrinol (Lausanne). 2020 Apr 16;11:191. doi: 10.3389/fendo.2020.00191. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32425881 Free PMC article. Review.
Metformin is a widely used biguanide drug due to its safety and low cost. It has been used for over 60 years to treat type 2 diabetes at the early stages because of its outstanding ability to decrease plasma glucose levels. Over time, different uses of metformin wer
Metformin is a widely used biguanide drug due to its safety and low cost. It has been used for over 60 years to treat type 2 diabetes
Metformin and the gastrointestinal tract.
McCreight LJ, Bailey CJ, Pearson ER. McCreight LJ, et al. Diabetologia. 2016 Mar;59(3):426-35. doi: 10.1007/s00125-015-3844-9. Epub 2016 Jan 16. Diabetologia. 2016. PMID: 26780750 Free PMC article. Review.
A novel delayed-release preparation of metformin has recently been shown to improve glycaemic control to a similar extent to immediate-release metformin, but with less systemic exposure. ...This review examines the passage of metformin through the gut, and ho …
A novel delayed-release preparation of metformin has recently been shown to improve glycaemic control to a similar extent to immediat …
Metformin-associated lactic acidosis: Current perspectives on causes and risk.
DeFronzo R, Fleming GA, Chen K, Bicsak TA. DeFronzo R, et al. Metabolism. 2016 Feb;65(2):20-9. doi: 10.1016/j.metabol.2015.10.014. Epub 2015 Oct 9. Metabolism. 2016. PMID: 26773926 Free article. Review.
Elevated plasma metformin concentrations (as occur in individuals with renal impairment) and a secondary event or condition that further disrupts lactate production or clearance (e.g., cirrhosis, sepsis, or hypoperfusion), are typically necessary to cause metformin- …
Elevated plasma metformin concentrations (as occur in individuals with renal impairment) and a secondary event or condition that furt …
Metformin in cancer.
Mallik R, Chowdhury TA. Mallik R, et al. Diabetes Res Clin Pract. 2018 Sep;143:409-419. doi: 10.1016/j.diabres.2018.05.023. Epub 2018 May 26. Diabetes Res Clin Pract. 2018. PMID: 29807101 Review.
Metformin is a lipophilic biguanide which inhibits hepatic gluconeogenesis and improves peripheral utilization of glucose. ...Recent randomised studies reporting use of metformin in treatment of cancer have revealed mixed results, and the results of much larger rand
Metformin is a lipophilic biguanide which inhibits hepatic gluconeogenesis and improves peripheral utilization of glucose. ...Recent
Metformin: clinical use in type 2 diabetes.
Sanchez-Rangel E, Inzucchi SE. Sanchez-Rangel E, et al. Diabetologia. 2017 Sep;60(9):1586-1593. doi: 10.1007/s00125-017-4336-x. Epub 2017 Aug 2. Diabetologia. 2017. PMID: 28770321 Review.
Metformin is one of the most popular oral glucose-lowering medications, widely considered to be the optimal initial therapy for patients with type 2 diabetes mellitus. ...With no long-term studies comparing it against newer glucose-lowering drugs, some of which have more r
Metformin is one of the most popular oral glucose-lowering medications, widely considered to be the optimal initial therapy for patie
Metformin: historical overview.
Bailey CJ. Bailey CJ. Diabetologia. 2017 Sep;60(9):1566-1576. doi: 10.1007/s00125-017-4318-z. Epub 2017 Aug 3. Diabetologia. 2017. PMID: 28776081
Guanidine derivatives, including metformin, were synthesised and some (not metformin) were used to treat diabetes in the 1920s and 1930s but were discontinued due to toxicity and the increased availability of insulin. ...Metformin's future was precario …
Guanidine derivatives, including metformin, were synthesised and some (not metformin) were used to treat diabetes in the 1920s …
Metformin--mode of action and clinical implications for diabetes and cancer.
Pernicova I, Korbonits M. Pernicova I, et al. Nat Rev Endocrinol. 2014 Mar;10(3):143-56. doi: 10.1038/nrendo.2013.256. Epub 2014 Jan 7. Nat Rev Endocrinol. 2014. PMID: 24393785 Review.
Metformin has been the mainstay of therapy for diabetes mellitus for many years; however, the mechanistic aspects of metformin action remained ill-defined. ...The knowledge gained from dissecting the principal mechanisms by which metformin works can help us t
Metformin has been the mainstay of therapy for diabetes mellitus for many years; however, the mechanistic aspects of metformin
Metformin: New Preparations and Nonglycemic Benefits.
Fujita Y, Inagaki N. Fujita Y, et al. Curr Diab Rep. 2017 Jan;17(1):5. doi: 10.1007/s11892-017-0829-8. Curr Diab Rep. 2017. PMID: 28116648 Review.
Delayed-release metformin acts in the lower gastrointestinal tract and exerts glucose-lowering effects at lower plasma metformin levels, which might suggest use of this biguanide in patients with chronic kidney disease. ...Anticancer effects of metformin have …
Delayed-release metformin acts in the lower gastrointestinal tract and exerts glucose-lowering effects at lower plasma metformin
25,789 results
You have reached the last available page of results. Please see the User Guide for more information.